

Sub. B1

10

Year	1955	1956	1957	1958	1959	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100																											
Population	1,000,000	1,050,000	1,100,000	1,150,000	1,200,000	1,250,000	1,300,000	1,350,000	1,400,000	1,450,000	1,500,000	1,550,000	1,600,000	1,650,000	1,700,000	1,750,000	1,800,000	1,850,000	1,900,000	1,950,000	2,000,000	2,050,000	2,100,000	2,150,000	2,200,000	2,250,000	2,300,000	2,350,000	2,400,000	2,450,000	2,500,000	2,550,000	2,600,000	2,650,000	2,700,000	2,750,000	2,800,000	2,850,000	2,900,000	2,950,000	3,000,000	3,050,000	3,100,000	3,150,000	3,200,000	3,250,000	3,300,000	3,350,000	3,400,000	3,450,000	3,500,000	3,550,000	3,600,000	3,650,000	3,700,000	3,750,000	3,800,000	3,850,000	3,900,000	3,950,000	4,000,000	4,050,000	4,100,000	4,150,000	4,200,000	4,250,000	4,300,000	4,350,000	4,400,000	4,450,000	4,500,000	4,550,000	4,600,000	4,650,000	4,700,000	4,750,000	4,800,000	4,850,000	4,900,000	4,950,000	5,000,000	5,050,000	5,100,000	5,150,000	5,200,000	5,250,000	5,300,000	5,350,000	5,400,000	5,450,000	5,500,000	5,550,000	5,600,000	5,650,000	5,700,000	5,750,000	5,800,000	5,850,000	5,900,000	5,950,000	6,000,000	6,050,000	6,100,000	6,150,000	6,200,000	6,250,000	6,300,000	6,350,000	6,400,000	6,450,000	6,500,000	6,550,000	6,600,000	6,650,000	6,700,000	6,750,000	6,800,000	6,850,000	6,900,000	6,950,000	7,000,000	7,050,000	7,100,000	7,150,000	7,200,000	7,250,000	7,300,000	7,350,000	7,400,000	7,450,000	7,500,000	7,550,000	7,600,000	7,650,000	7,700,000	7,750,000	7,800,000	7,850,000	7,900,000	7,950,000	8,000,000	8,050,000	8,100,000	8,150,000	8,200,000	8,250,000	8,300,000	8,350,000	8,400,000	8,450,000	8,500,000	8,550,000	8,600,000	8,650,000	8,700,000	8,750,000	8,800,000	8,850,000	8,900,000	8,950,000	9,000,000	9,050,000	9,100,000	9,150,000	9,200,000	9,250,000	9,300,000	9,350,000	9,400,000	9,450,000	9,500,000	9,550,000	9,600,000

15

20

25

30

35

12. The therapeutic agent according to ~~any of~~<sup>claim 11</sup>  
~~claims 1 through 11~~, in which the anti-IL-8 antibody has  
the constant region of human antibody.

a  
a  
13. The therapeutic agent according to <sup>claim 1</sup> ~~any of~~ ~~claims 1 through 12~~, in which the anti-IL-8 antibody is a humanized or chimeric antibody.

Q  
5 14. The therapeutic agent according to <sup>claim 1</sup> ~~any of~~ ~~claims 1 through 13~~, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

15. A therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as an active ingredient.

Sub 7  
B2  
10 16. Use of anti-IL-8 antibody for production of a therapeutic agent for treatment of acute lung injury resulting from indirect causes.

a  
17. <sup>A process</sup> ~~Use~~ according to claim 16 in which the acute lung injury is acute respiratory distress syndrome.

15 18. <sup>A process</sup> ~~Use~~ according to claim 16 in which the acute lung injury is adult respiratory distress syndrome.

19. <sup>A process</sup> ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is the sepsis syndrome.

20 20. <sup>A process</sup> ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is severe nonthoracic trauma.

21. <sup>A process</sup> ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is hypertransfusion during emergency resuscitation.

a  
25 22. <sup>A process</sup> ~~Use~~ according to any of claims 16, 17, and 18, in which the indirect cause is an artificial cardiopulmonary bypass surgery.

Sub 7  
Q2  
23. Use according to any of claims 16 through 22, in which the anti-IL-8 antibody is a monoclonal antibody.

30 24. Use according to any of claims 16 through 23, in which the anti-IL-8 antibody is an antibody against mammalian IL-8.

25. Use according to any of claims 16 through 24, in which the anti-IL-8 antibody is an antibody against human IL-8.

35 26. Use according to any of claims 16 through 25, in which the anti-IL-8 antibody is WS-4 antibody.

27. Use according to any of claims 16 through 26,

Sub 2  
in which the anti-IL-8 antibody has the constant region of human antibody.

28. Use according to any of claims 16 through 27, in which the anti-IL-8 antibody is a humanized or  
5 chimeric antibody.

29. Use according to any of claims 16 through 28, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

30. Use of anti-IL-8 antibody for production of a  
10 therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes.

31. A therapeutic method for treatment of acute lung injury resulting from indirect causes, which method comprises administering anti-IL-8 antibody to a subject  
15 in need of said therapy.

32. The method according to claim 31 in which the acute lung injury is acute respiratory distress syndrome.

33. The method according to claim 31 in which the acute lung injury is adult respiratory distress syndrome.

34. The method according to any of claims 31, 32, and 33, in which the indirect cause is the sepsis syndrome.  
20

35. The method according to any of claims 31, 32, and 33, in which the indirect cause is severe nonthoracic trauma.  
25

36. The method according to any of claims 31, 32, and 33, in which the indirect cause is hypertransfusion during emergency resuscitation.

37. The method according to any of claims 31, 32, and 33, in which the indirect cause is an artificial  
30 cardiopulmonary bypass surgery.

38. The method according to <sup>claim 31</sup> ~~any of claims 31 through 37~~, in which the anti-IL-8 antibody is a monoclonal antibody.

39. The method according to <sup>claim 31</sup> ~~any of claims 31 through 38~~, in which the anti-IL-8 antibody is an antibody against mammalian IL-8.  
35

40. The method according to <sup>claim 31</sup> ~~any of claims 31 through 39~~, in which the anti-IL-8 antibody is an antibody against human IL-8.

41. The method according to <sup>claim 31</sup> ~~any of claims 31 through 40~~, in which the anti-IL-8 antibody is WS-4 antibody.

42. The method according to <sup>claim 31</sup> ~~any of claims 31 through 41~~, in which the anti-IL-8 antibody has the constant region of human antibody.

43. The method according to <sup>claim 31</sup> ~~any of claims 31 through 42~~, in which the anti-IL-8 antibody is a humanized or chimeric antibody.

44. The method according to <sup>claim 31</sup> ~~any of claims 31 through 43~~, in which the anti-IL-8 antibody is a humanized WS-4 antibody.

45. Use of anti-IL-8 antibody for production of a therapeutic agent for hypoxemia in acute lung injury resulting from indirect causes.